Denteric is developing therapies to treat Porphyromonas gingivalis related diseases. Our initial focus is on severe periodontal disease. Our vaccine therapy aims to generate antibodies that neutralise the proteolytic toxins of the bacteria that cause periodontal disease and inflammation. We are currently in phase I clinical trials.
| Website | https://www.denteric.com |
| Employees | 10 (6 on RocketReach) |
| Founded | 2019 |
| Address | 31 Queen St, Melbourne, Victoria 3000, AU |
| Industry | Biotechnology Research, Drug Discovery, Biotechnology |
| Keywords | Periodontitis Treatment, Gingivitis Treatment, Gum Disease Treatment, Oral Health, Dental Health, Bacterial Infections, Immunotherapy, Oral Microbiome, Therapeutic Antibodies, Disease Prevention, Infectious Disease, Biologics, Novel Therapies |
| Competitors | 3M, Henry Schein, Align Technology, Patterson Dental, SmileDirectClub, ClearCorrect, OrthoFX, Invisalign Orthodontist US, Snap-On Smile, Cerec +29 more (view full list) |
Looking for a particular Denteric employee's phone or email?
Larisa Chisholm is the COO of Denteric.
6 people are employed at Denteric.
Denteric is based in Melbourne, Victoria.